JP2017149960A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017149960A5 JP2017149960A5 JP2017058554A JP2017058554A JP2017149960A5 JP 2017149960 A5 JP2017149960 A5 JP 2017149960A5 JP 2017058554 A JP2017058554 A JP 2017058554A JP 2017058554 A JP2017058554 A JP 2017058554A JP 2017149960 A5 JP2017149960 A5 JP 2017149960A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- nanocarrier
- acid
- compound
- linker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002539 nanocarrier Substances 0.000 claims 17
- 150000001875 compounds Chemical class 0.000 claims 9
- 239000004380 Cholic acid Substances 0.000 claims 7
- 239000002202 Polyethylene glycol Substances 0.000 claims 7
- 229960002471 cholic acid Drugs 0.000 claims 7
- 229920001223 polyethylene glycol Polymers 0.000 claims 7
- 230000002209 hydrophobic effect Effects 0.000 claims 5
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 claims 4
- -1 2,3-dihydroxy-1-propoxy Chemical group 0.000 claims 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 4
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 claims 4
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 claims 4
- 235000019416 cholic acid Nutrition 0.000 claims 4
- 239000002872 contrast media Substances 0.000 claims 4
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 125000003716 cholic acid group Chemical group 0.000 claims 3
- YQUVCSBJEUQKSH-UHFFFAOYSA-N 3,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 claims 2
- JJMDCOVWQOJGCB-UHFFFAOYSA-N 5-aminopentanoic acid Chemical compound [NH3+]CCCCC([O-])=O JJMDCOVWQOJGCB-UHFFFAOYSA-N 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 2
- YEYCQJVCAMFWCO-UHFFFAOYSA-N [10,13-dimethyl-17-(6-methylheptan-2-yl)-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] formate Chemical compound C1C=C2CC(OC=O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 YEYCQJVCAMFWCO-UHFFFAOYSA-N 0.000 claims 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims 2
- 238000010504 bond cleavage reaction Methods 0.000 claims 2
- 238000004132 cross linking Methods 0.000 claims 2
- 229960004679 doxorubicin Drugs 0.000 claims 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000000178 monomer Substances 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 239000002096 quantum dot Substances 0.000 claims 2
- KWNPRVWFJOSGMZ-UHFFFAOYSA-N 2-boronobenzoic acid Chemical compound OB(O)C1=CC=CC=C1C(O)=O KWNPRVWFJOSGMZ-UHFFFAOYSA-N 0.000 claims 1
- NSOQPFCRCLZMRT-UHFFFAOYSA-N 3-borono-2-nitrobenzoic acid Chemical compound OB(O)C1=CC=CC(C(O)=O)=C1[N+]([O-])=O NSOQPFCRCLZMRT-UHFFFAOYSA-N 0.000 claims 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 claims 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims 1
- FJHBVJOVLFPMQE-QFIPXVFZSA-N 7-Ethyl-10-Hydroxy-Camptothecin Chemical compound C1=C(O)C=C2C(CC)=C(CN3C(C4=C([C@@](C(=O)OC4)(O)CC)C=C33)=O)C3=NC2=C1 FJHBVJOVLFPMQE-QFIPXVFZSA-N 0.000 claims 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims 1
- 239000005153 Cholesterol Formate Substances 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 claims 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 1
- 229960002684 aminocaproic acid Drugs 0.000 claims 1
- 239000003125 aqueous solvent Substances 0.000 claims 1
- 229940000635 beta-alanine Drugs 0.000 claims 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims 1
- 229960001467 bortezomib Drugs 0.000 claims 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 1
- 229940127093 camptothecin Drugs 0.000 claims 1
- 229960005243 carmustine Drugs 0.000 claims 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 claims 1
- 229960000975 daunorubicin Drugs 0.000 claims 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- 229960003957 dexamethasone Drugs 0.000 claims 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 1
- 229960005420 etoposide Drugs 0.000 claims 1
- 239000007850 fluorescent dye Substances 0.000 claims 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims 1
- 239000010931 gold Substances 0.000 claims 1
- 229910052737 gold Inorganic materials 0.000 claims 1
- 125000001165 hydrophobic group Chemical group 0.000 claims 1
- 230000005661 hydrophobic surface Effects 0.000 claims 1
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 claims 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 1
- 229960004891 lapatinib Drugs 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 229940031182 nanoparticles iron oxide Drugs 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 108010094020 polyglycine Proteins 0.000 claims 1
- 229920000232 polyglycine polymer Polymers 0.000 claims 1
- 108010000222 polyserine Proteins 0.000 claims 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 1
- 229960004618 prednisone Drugs 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 229960000235 temsirolimus Drugs 0.000 claims 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 claims 1
- 229960003048 vinblastine Drugs 0.000 claims 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 1
- 229960004528 vincristine Drugs 0.000 claims 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161485774P | 2011-05-13 | 2011-05-13 | |
| US61/485,774 | 2011-05-13 | ||
| US201161487953P | 2011-05-19 | 2011-05-19 | |
| US61/487,953 | 2011-05-19 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014510540A Division JP6235460B6 (ja) | 2011-05-13 | 2012-05-14 | 可逆的に架橋されたミセルｓｙｓｔｅｍｓ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017149960A JP2017149960A (ja) | 2017-08-31 |
| JP2017149960A5 true JP2017149960A5 (enExample) | 2018-01-11 |
| JP6542827B2 JP6542827B2 (ja) | 2019-07-10 |
Family
ID=47177586
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017058554A Active JP6542827B2 (ja) | 2011-05-13 | 2017-03-24 | 可逆的に架橋されたミセル系 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US10106650B2 (enExample) |
| EP (1) | EP2707419B1 (enExample) |
| JP (1) | JP6542827B2 (enExample) |
| CN (1) | CN103748142B (enExample) |
| WO (1) | WO2012158622A2 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2915692T3 (es) | 2008-08-13 | 2022-06-24 | California Inst Of Techn | Nanopartículas portadoras y composiciones, métodos y sistemas relacionados |
| EP2707419B1 (en) | 2011-05-13 | 2019-08-14 | The Regents of The University of California | Reversibly crosslinked micelle systems |
| HK1198628A1 (en) * | 2011-08-12 | 2015-05-22 | Ascendis Pharma A/S | Polymeric hyperbranched carrier-linked prodrugs |
| CN104105508B (zh) | 2011-12-21 | 2017-10-24 | 加利福尼亚大学董事会 | 药物递送增强的末端树枝状聚合物 |
| US9642916B2 (en) | 2012-12-12 | 2017-05-09 | The Regents Of The University Of California | Porphyrin modified telodendrimers |
| US9468681B2 (en) | 2013-03-01 | 2016-10-18 | California Institute Of Technology | Targeted nanoparticles |
| ES2986545T3 (es) * | 2013-03-01 | 2024-11-11 | California Inst Of Techn | Nanopartículas dirigidas |
| EP2961788B1 (en) * | 2013-03-01 | 2019-05-08 | California Institute of Technology | Nanoparticles stabilized with nitrophenylboronic acid compositions |
| CA3166758A1 (en) | 2013-05-14 | 2014-11-20 | California Institute Of Technology | Method of delivering therapeutics and imaging agents by nanoparticles that cross the blood brain barrier |
| CN104414973A (zh) * | 2013-08-21 | 2015-03-18 | 复旦大学 | 一种视黄酸和紫杉醇共递药的胶束给药系统及其制备方法 |
| US11406714B2 (en) | 2013-08-21 | 2022-08-09 | The Research Foundation For The State University Of New York | Telodendrimers and nanocarriers and methods of using same |
| CN105193732A (zh) * | 2014-06-05 | 2015-12-30 | 华东理工大学 | 雷帕霉素纳米缓释微球及其制备方法 |
| CN104530413B (zh) * | 2014-10-01 | 2017-08-25 | 厦门赛诺邦格生物科技股份有限公司 | 一种多官能化h型聚乙二醇衍生物修饰的生物相关物质 |
| WO2016050208A1 (zh) * | 2014-10-01 | 2016-04-07 | 厦门赛诺邦格生物科技有限公司 | 一种多官能化聚乙二醇衍生物修饰的生物相关物质 |
| WO2016050210A1 (zh) * | 2014-10-01 | 2016-04-07 | 厦门赛诺邦格生物科技有限公司 | 一种多官能化聚乙二醇衍生物及其制备方法 |
| CN104530417B (zh) * | 2014-10-01 | 2017-09-08 | 厦门赛诺邦格生物科技股份有限公司 | 一种多官能化h型聚乙二醇衍生物及其制备方法 |
| WO2016057657A1 (en) * | 2014-10-07 | 2016-04-14 | The Research Foundation For The State University Of New York | Functional segregated telodendrimers and nanocarriers and methods of making and using same |
| EP3317323B1 (en) | 2015-07-01 | 2021-05-26 | California Institute of Technology | Cationic mucic acid polymer-based delivery systems |
| ES2625024B1 (es) * | 2015-12-18 | 2018-05-10 | Consejo Superior De Investigaciones Cientificas | Material que comprende tectómeros de oligoglicina y nanohilos |
| CN109562078A (zh) * | 2016-03-03 | 2019-04-02 | 特瑞奥纳米有限公司 | 多药物复合物、其制备方法及用途 |
| US10517823B1 (en) | 2016-08-10 | 2019-12-31 | Verily Life Sciences Llc | ROS—responsive liposomes for specific targeting |
| US10583083B1 (en) * | 2016-08-10 | 2020-03-10 | Verily Life Sciences Llc | ROS-responsive multilamellar liposomal vesicles for targeting inflammatory macrophages |
| CN110392583B (zh) * | 2016-09-15 | 2023-01-03 | 加利福尼亚大学董事会 | 改进的杂化的末端树枝状聚合物 |
| WO2018136778A1 (en) | 2017-01-19 | 2018-07-26 | The Research Foundation For The State University Of New York | Telodendrimers with riboflavin moieties and nanocarriers and methods of making and using same |
| JP2018058868A (ja) * | 2017-11-24 | 2018-04-12 | カリフォルニア インスティテュート オブ テクノロジー | ニトロフェニルボロン酸組成物によって安定化したナノ粒子 |
| JP2018070626A (ja) * | 2017-11-24 | 2018-05-10 | カリフォルニア インスティテュート オブ テクノロジー | 標的化ナノ粒子 |
| JP7525981B2 (ja) * | 2017-11-24 | 2024-07-31 | カリフォルニア インスティテュート オブ テクノロジー | ニトロフェニルボロン酸組成物によって安定化したナノ粒子 |
| US20190381188A1 (en) | 2018-06-13 | 2019-12-19 | California Institute Of Technology | Nanoparticles For Crossing The Blood Brain Barrier And Methods Of Treatment Using The Same |
| CN112584867B (zh) * | 2018-08-13 | 2024-12-13 | 聚合物工厂瑞典公司 | 树枝状纳米凝胶载体及其生产方法 |
| US12527880B2 (en) | 2018-08-31 | 2026-01-20 | The Regents Of The University Of California | Cyanine-based telodendrimers and uses for treating cancer |
| CN111184874B (zh) * | 2018-11-14 | 2022-02-22 | 南京大学 | 疏水性纳米生物探针 |
| US11179475B2 (en) | 2018-11-28 | 2021-11-23 | International Business Machines Corporation | Biodegradable functional polycarbonate nanoparticle carries for delivering molecular cargo |
| JP2019108371A (ja) * | 2019-03-04 | 2019-07-04 | カリフォルニア インスティテュート オブ テクノロジー | 標的化ナノ粒子 |
| CN111904932B (zh) * | 2019-05-08 | 2023-06-20 | 北京德立福瑞医药科技有限公司 | 一种含有糖皮质激素的胶束制剂及其制备方法 |
| WO2021113643A2 (en) | 2019-12-04 | 2021-06-10 | Dantari, Inc. | Methods and compositions for synthesis of therapeutic nanoparticles |
| US20230076792A1 (en) * | 2019-12-17 | 2023-03-09 | The Regents Of The University Of California | Sequential targeting in crosslinking nano-theranostics for treating brain tumors |
| EP4429798A4 (en) * | 2021-11-09 | 2026-01-21 | Massachusetts Inst Technology | PARTICLES CONTAINING POLLUTANT CAPTURE MICELLES AND ASSOCIATED PROCESSES |
| EP4460313A4 (en) * | 2022-01-04 | 2026-01-14 | Univ New York State Res Found | CMT-3 FORMULATIONS AND THEIR METHODS OF USE |
| CN115531291B (zh) * | 2022-09-02 | 2025-02-14 | 南京医科大学 | 一种可载药的赖氨大黄酸自组装水凝胶及其制备方法与应用 |
| WO2024254448A2 (en) * | 2023-06-07 | 2024-12-12 | The Research Foundation For The State University Of New York | Boronate prodrug nanoformulations in disease treatments |
| CN121064464B (zh) * | 2025-11-06 | 2026-02-24 | 北京师范大学珠海校区 | 一种基于天然分子胆酸的抗菌牙科树脂材料 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000009133A1 (fr) | 1998-08-10 | 2000-02-24 | Asahi Kasei Kogyo Kabushiki Kaisha | Preparations orales, a liberation prolongee, a base de chlorhydrate de fasudil |
| JP4659937B2 (ja) | 1999-11-19 | 2011-03-30 | ナノキャリア株式会社 | コア−シェル構造のポリイオンコンプレックスミセル |
| AU2002953073A0 (en) * | 2002-11-21 | 2003-01-16 | Access Pharmaceuticals Australia Pty Limited | Amplification of biotin-mediated targeting |
| US7846893B2 (en) | 2005-02-16 | 2010-12-07 | Rutgers, The State University Of New Jersey | Drug-polymer conjugates coupled to a peptidic carrier |
| US8153110B2 (en) | 2006-11-22 | 2012-04-10 | The University Of Tokyo | Environment-responding siRNA carrier using disulfide-cross-linked polymeric micelle |
| JP5539993B2 (ja) * | 2008-09-23 | 2014-07-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 薬物送達のためのナノ担体 |
| US9296988B2 (en) | 2009-06-19 | 2016-03-29 | The Regents Of The University Of California | Three-dimensional cell adhesion matrix |
| EP2707419B1 (en) | 2011-05-13 | 2019-08-14 | The Regents of The University of California | Reversibly crosslinked micelle systems |
-
2012
- 2012-05-14 EP EP12786464.3A patent/EP2707419B1/en active Active
- 2012-05-14 CN CN201280032611.3A patent/CN103748142B/zh active Active
- 2012-05-14 US US14/117,570 patent/US10106650B2/en active Active
- 2012-05-14 WO PCT/US2012/037794 patent/WO2012158622A2/en not_active Ceased
-
2017
- 2017-03-24 JP JP2017058554A patent/JP6542827B2/ja active Active
-
2018
- 2018-09-14 US US16/131,644 patent/US11192978B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016511222A5 (enExample) | ||
| Aiertza et al. | Single-chain polymer nanoparticles | |
| Yang et al. | pH-sensitive micelles self-assembled from amphiphilic copolymer brush for delivery of poorly water-soluble drugs | |
| Lee et al. | Hyperbranched double hydrophilic block copolymer micelles of poly (ethylene oxide) and polyglycerol for pH-responsive drug delivery | |
| Li et al. | One-step preparation of pH-responsive polymeric nanogels as intelligent drug delivery systems for tumor therapy | |
| Drbohlavova et al. | Nanocarriers for anticancer drugs-new trends in nanomedicine | |
| Wang et al. | Multifunctional chitosan magnetic-graphene (CMG) nanoparticles: a theranostic platform for tumor-targeted co-delivery of drugs, genes and MRI contrast agents | |
| Ghaz-Jahanian et al. | Application of chitosan-based nanocarriers in tumor-targeted drug delivery | |
| Prabaharan | Chitosan-based nanoparticles for tumor-targeted drug delivery | |
| US10568970B2 (en) | Theranostic compositions and uses thereof | |
| US20190029970A1 (en) | Fatty acid conjugated nanoparticles and uses thereof | |
| Jia et al. | Unimolecular micelles of amphiphilic cyclodextrin-core star-like copolymers with covalent pH-responsive linkage of anticancer prodrugs | |
| Lin et al. | Doxorubicin-loaded unimolecular micelle-stabilized gold nanoparticles as a theranostic nanoplatform for tumor-targeted chemotherapy and computed tomography imaging | |
| Qian et al. | Folate-decorated hydrophilic three-arm star-block terpolymer as a novel nanovehicle for targeted co-delivery of doxorubicin and Bcl-2 siRNA in breast cancer therapy | |
| Aliabadi et al. | Synthesis approaches of amphiphilic copolymers for spherical micelle preparation: application in drug delivery | |
| Hamidi et al. | Copolymers: efficient carriers for intelligent nanoparticulate drug targeting and gene therapy | |
| Huang et al. | Dual stimuli-responsive polymer prodrugs quantitatively loaded by nanoparticles for enhanced cellular internalization and triggered drug release | |
| JP2012503603A5 (enExample) | ||
| Suo et al. | Comb-like amphiphilic polypeptide-based copolymer nanomicelles for co-delivery of doxorubicin and P-gp siRNA into MCF-7 cells | |
| CN102414116A (zh) | 用于制备尺寸可控的纳米颗粒的超分子方法 | |
| Luo et al. | Solute-triggered morphological transitions of an amphiphilic heterografted brush copolymer as a single-molecule drug carrier | |
| Liu et al. | Zwitterionic unimolecular micelles with pH and temperature response: enhanced in vivo circulation stability and tumor therapeutic efficiency | |
| JP4824710B2 (ja) | グラフト共重合体およびブロック共重合体の多機能混合ミセルならびにその製造方法 | |
| Nair K et al. | Folic acid conjugated δ-valerolactone-poly (ethylene glycol) based triblock copolymer as a promising carrier for targeted doxorubicin delivery | |
| Saleem et al. | Nanodrugs: magic bullets in cancer chemotherapy |